Published in Proc Natl Acad Sci U S A on August 31, 1999
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev (2003) 6.17
Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol (2003) 4.70
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J (2001) 3.42
Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol (2003) 2.79
Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol Cell Biol (2007) 2.67
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A (2001) 2.39
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol (2014) 2.01
Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J (2003) 1.89
Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci (2009) 1.87
The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol (2007) 1.84
The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci (2009) 1.82
Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci U S A (2001) 1.74
Proteasome function is required for biological timing throughout the twenty-four hour cycle. Curr Biol (2011) 1.70
Phytoplasma effector SAP54 hijacks plant reproduction by degrading MADS-box proteins and promotes insect colonization in a RAD23-dependent manner. PLoS Biol (2014) 1.66
Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J Virol (2007) 1.65
Equine infectious anemia virus and the ubiquitin-proteasome system. J Virol (2002) 1.63
Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol (2002) 1.58
Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol Cell Biol (2002) 1.49
CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med (2004) 1.47
Proteasome inhibition by fellutamide B induces nerve growth factor synthesis. Chem Biol (2008) 1.45
Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons. J Virol (2003) 1.41
Large-scale identification of ubiquitination sites by mass spectrometry. Nat Protoc (2013) 1.41
High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget (2012) 1.34
The proteasome inhibitor epoxomicin has potent Plasmodium falciparum gametocytocidal activity. Antimicrob Agents Chemother (2009) 1.32
Binding of LARP6 to the conserved 5' stem-loop regulates translation of mRNAs encoding type I collagen. J Mol Biol (2009) 1.30
Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step. J Virol (2008) 1.30
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol (2014) 1.29
Degradation of an intramitochondrial protein by the cytosolic proteasome. J Cell Sci (2010) 1.29
Ubiquitination and proteasomal degradation of interferon regulatory factor-3 induced by Npro from a cytopathic bovine viral diarrhea virus. Virology (2007) 1.28
Aging and regulated protein degradation: who has the UPPer hand? Aging Cell (2007) 1.27
Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J (2006) 1.27
Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J (2008) 1.27
Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2003) 1.26
Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev Proteomics (2008) 1.26
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood (2010) 1.25
Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs (2009) 1.22
Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J Virol (2009) 1.22
Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. Angew Chem Int Ed Engl (2010) 1.22
Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol (2015) 1.21
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol (2000) 1.20
Two-dimensional patterning by a trapping/depletion mechanism: the role of TTG1 and GL3 in Arabidopsis trichome formation. PLoS Biol (2008) 1.19
Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew Chem Int Ed Engl (2014) 1.18
Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol (2003) 1.18
Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol (2008) 1.17
Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha proinflammatory signaling by inhibition of NF-kappaB activation. J Virol (2006) 1.17
A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem (2010) 1.15
Cytoplasmic trafficking of minute virus of mice: low-pH requirement, routing to late endosomes, and proteasome interaction. J Virol (2002) 1.13
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13
Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol (2005) 1.12
Current advances in detection and treatment of babesiosis. Curr Med Chem (2012) 1.11
Proteasome inhibitors and cardiac cell growth. Cardiovasc Res (2009) 1.10
Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition. Biochem J (2004) 1.08
TRIM9, a novel brain-specific E3 ubiquitin ligase, is repressed in the brain of Parkinson's disease and dementia with Lewy bodies. Neurobiol Dis (2010) 1.08
Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proc Natl Acad Sci U S A (2009) 1.07
Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc Natl Acad Sci U S A (2000) 1.07
PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. Biochem J (2013) 1.07
Constitutive endocytosis and degradation of the pre-T cell receptor. J Exp Med (2002) 1.05
Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement. Proc Natl Acad Sci U S A (2001) 1.05
Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol (2010) 1.05
Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem (2012) 1.05
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem Lett (2008) 1.05
Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS One (2007) 1.04
From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des (2013) 1.04
The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle. J Virol (2010) 1.04
A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing. J Neurosci (2010) 1.03
Modulation of skeletal muscle insulin signaling with chronic caloric restriction in cynomolgus monkeys. Diabetes (2009) 1.03
Endoplasmic reticulum degradation impedes olfactory G-protein coupled receptor functional expression. BMC Cell Biol (2004) 1.03
Isolevuglandin-modified proteins, including elevated levels of inactive calpain-1, accumulate in glaucomatous trabecular meshwork. Biochemistry (2007) 1.02
Dependence of proteasome processing rate on substrate unfolding. J Biol Chem (2011) 1.02
Fates-shifted is an F-box protein that targets Bicoid for degradation and regulates developmental fate determination in Drosophila embryos. Nat Cell Biol (2010) 1.02
Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function. Inflamm Bowel Dis (2009) 1.01
TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther (2012) 1.01
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLoS One (2014) 1.00
A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem Biophys Res Commun (2009) 0.99
Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. J Virol (2003) 0.99
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. ACS Chem Biol (2015) 0.99
Functional importance of the anaphase-promoting complex-Cdh1-mediated degradation of TMAP/CKAP2 in regulation of spindle function and cytokinesis. Mol Cell Biol (2007) 0.99
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc Natl Acad Sci U S A (2001) 0.98
From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep (2013) 0.98
Acute decreases in proteasome pathway activity after inhalation of fresh diesel exhaust or secondary organic aerosol. Environ Health Perspect (2010) 0.97
Relative quantification of proteasome activity by activity-based protein profiling and LC-MS/MS. Nat Protoc (2013) 0.96
Intermediate filament transcription in astrocytes is repressed by proteasome inhibition. FASEB J (2009) 0.95
Development of withaferin A analogs as probes of angiogenesis. Bioorg Med Chem Lett (2006) 0.95
Cardiac muscle protein catabolism in diabetes mellitus: activation of the ubiquitin-proteasome system by insulin deficiency. Endocrinology (2008) 0.95
Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: potential application to choroidal neovascularization. Invest Ophthalmol Vis Sci (2006) 0.95
The carmaphycins: new proteasome inhibitors exhibiting an α,β-epoxyketone warhead from a marine cyanobacterium. Chembiochem (2012) 0.95
Inhibition of proteasome activity strongly affects kiwifruit pollen germination. Involvement of the ubiquitin/proteasome pathway as a major regulator. Plant Physiol (2001) 0.94
Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol (2006) 0.93
Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments. PLoS One (2011) 0.93
TFF3 modulates NF-{kappa}B and a novel negative regulatory molecule of NF-{kappa}B in intestinal epithelial cells via a mechanism distinct from TNF-{alpha}. Am J Physiol Cell Physiol (2005) 0.93
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides. J Proteome Res (2012) 0.92
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Structure of 20S proteasome from yeast at 2.4 A resolution. Nature (1997) 12.73
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 11.62
Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem (1996) 10.70
Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell (1994) 8.65
Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science (1995) 8.58
Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol (1998) 7.27
The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J (1998) 6.37
The ubiquitin system. Trends Biochem Sci (1997) 4.67
A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J (1994) 4.04
MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature (1993) 3.18
Proteasomes: destruction as a programme. Trends Biochem Sci (1996) 3.15
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A (1997) 2.81
PRE2, highly homologous to the human major histocompatibility complex-linked RING10 gene, codes for a yeast proteasome subunit necessary for chrymotryptic activity and degradation of ubiquitinated proteins. J Biol Chem (1993) 2.71
Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem (1997) 2.39
Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J Exp Med (1991) 2.24
The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity (1995) 2.17
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
A giant protease with potential to substitute for some functions of the proteasome. Science (1999) 2.08
Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. Biochemistry (1992) 1.74
Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A (1998) 1.69
Delayed-type hypersensitivity is mediated by a sequence of two different T cell activities. J Immunol (1984) 1.65
The ubiquitin-proteasome pathway in cancer. Br J Cancer (1998) 1.56
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem Biol (1998) 1.51
Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) (1992) 1.44
Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L. Biochem J (1996) 1.37
Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling. J Biol Chem (1998) 1.36
Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 1.31
The ubiquitin-mediated proteolytic pathway as a therapeutic area. J Mol Med (Berl) (1997) 1.29
Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem Biophys Res Commun (1997) 1.26
Active site-directed inhibitors of Rhodococcus 20 S proteasome. Kinetics and mechanism. J Biol Chem (1997) 1.23
Structure-activity relationships of boronic acid inhibitors of dipeptidyl peptidase IV. 1. Variation of the P2 position of Xaa-boroPro dipeptides. J Med Chem (1996) 1.10
Possible involvement of C5/C5a in the efferent and elicitation phases of contact sensitivity. J Immunol (1996) 1.09
Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome. J Biol Chem (1997) 1.05
Eponemycin, a new antibiotic active against B16 melanoma. I. Production, isolation, structure and biological activity. J Antibiot (Tokyo) (1990) 1.03
Inhibitors of the chymotrypsin-like activity of proteasome based on di- and tri-peptidyl alpha-keto aldehydes (glyoxals). Bioorg Med Chem Lett (1998) 1.00
[Lactacystin: a tool for elucidation of proteasome functions]. Tanpakushitsu Kakusan Koso (1996) 0.87
Type IV reactions in the skin. Ann Allergy (1976) 0.85
Acquiring a four-dimensional computed tomography dataset using an external respiratory signal. Phys Med Biol (2003) 3.29
The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci U S A (1997) 3.23
Advances in microbial amylases. Biotechnol Appl Biochem (2000) 3.11
Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys (1996) 2.70
Acquiring 4D thoracic CT scans using a multislice helical method. Phys Med Biol (2004) 2.42
The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol (2001) 2.41
Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A (2001) 2.39
Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest (2003) 2.30
Motion adaptive x-ray therapy: a feasibility study. Phys Med Biol (2001) 2.21
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Japanese yew poisoning of large domestic animals in the Midwest. J Am Vet Med Assoc (1977) 2.07
Small-molecule inhibitors specifically targeting type III secretion. Infect Immun (2005) 2.02
Converting absorbed dose to medium to absorbed dose to water for Monte Carlo based photon beam dose calculations. Phys Med Biol (2000) 1.99
Reconstitution of the Raf-1-MEK-ERK signal transduction pathway in vitro. Mol Cell Biol (1993) 1.99
Sequence and expression of chicken and mouse rsk: homologs of Xenopus laevis ribosomal S6 kinase. Mol Cell Biol (1989) 1.96
Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science (1998) 1.94
Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys (1991) 1.89
Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci U S A (1992) 1.82
Phorbol ester stimulates a protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product. Proc Natl Acad Sci U S A (1992) 1.81
Quantifying the predictability of diaphragm motion during respiration with a noninvasive external marker. Med Phys (2003) 1.76
Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol (1999) 1.65
Dose-volume histograms. Int J Radiat Oncol Biol Phys (1991) 1.62
Algorithms and functionality of an intensity modulated radiotherapy optimization system. Med Phys (2000) 1.57
Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria. J Intern Med (2008) 1.54
The Gotfried percutaneous compression plate compared with the conventional classic hip screw for the fixation of intertrochanteric fractures of the hip. J Bone Joint Surg Br (2002) 1.54
Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett (1999) 1.54
When becometh less more? Int J Radiat Oncol Biol Phys (1995) 1.50
The biological basis for conformal three-dimensional radiation therapy. Int J Radiat Oncol Biol Phys (1991) 1.46
Optimization of intensity-modulated 3D conformal treatment plans based on biological indices. Radiother Oncol (1995) 1.46
Evacuation decisions in a chemical air pollution incident: cross sectional survey. BMJ (2005) 1.45
Raf-1 forms a stable complex with Mek1 and activates Mek1 by serine phosphorylation. Proc Natl Acad Sci U S A (1993) 1.44
Determining parameters for respiration-gated radiotherapy. Med Phys (2001) 1.43
Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys (1997) 1.42
The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys (2000) 1.38
Proteolytic mechanisms in corneal ulceration and repair. Arch Dermatol Res (1998) 1.36
Eponemycin analogues: syntheses and use as probes of angiogenesis. Bioorg Med Chem (1998) 1.34
Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol Cell (2001) 1.34
The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci U S A (2000) 1.33
Predicting respiratory motion for four-dimensional radiotherapy. Med Phys (2004) 1.33
Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res (1999) 1.31
Dynamic splitting of large intensity-modulated fields. Phys Med Biol (2000) 1.30
Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci (Lond) (1996) 1.30
Monte Carlo as a four-dimensional radiotherapy treatment-planning tool to account for respiratory motion. Phys Med Biol (2004) 1.24
Prevalence, antigenic specificity, and bactericidal activity of poultry anti-Campylobacter maternal antibodies. Appl Environ Microbiol (2001) 1.22
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol (2000) 1.20
Quantifying the effect of intrafraction motion during breast IMRT planning and dose delivery. Med Phys (2003) 1.20
The rubber hand illusion increases histamine reactivity in the real arm. Curr Biol (2011) 1.20
Assessment of the accuracy of an MCNPX-based Monte Carlo simulation model for predicting three-dimensional absorbed dose distributions. Phys Med Biol (2008) 1.18
Glycopeptides bind MHC molecules and elicit specific T cell responses. J Immunol (1993) 1.18
Pax-6 expression and activity are induced in the reepithelializing cornea and control activity of the transcriptional promoter for matrix metalloproteinase gelatinase B. Dev Biol (2000) 1.18
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene (2008) 1.17
Theoretical variance analysis of single- and dual-energy computed tomography methods for calculating proton stopping power ratios of biological tissues. Phys Med Biol (2010) 1.16
Comparison of EGS4 and MCNP4b Monte Carlo codes for generation of photon phase space distributions for a Varian 2100C. Phys Med Biol (1999) 1.15
Characteristics of high intent suicide attempters admitted to a general hospital. J Affect Disord (2006) 1.13
Potential radiotherapy improvements with respiratory gating. Australas Phys Eng Sci Med (2002) 1.12
Quantifying the accuracy of automated structure segmentation in 4D CT images using a deformable image registration algorithm. Med Phys (2008) 1.10
Quality of life after open heart surgery 16-18 May 1991. Qual Life Res (1992) 1.09
Commissioning dose computation models for spot scanning proton beams in water for a commercially available treatment planning system. Med Phys (2013) 1.08
The effect of setup uncertainty on normal tissue sparing with IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2001) 1.08
High prevalence of maturity-onset diabetes of the young (MODY) among Indians. Diabetes Care (1985) 1.05
Comparative study of monocomponent insulins and conventional insulins on the course of diabetic nephropathy. A follow-up study. J Assoc Physicians India (1990) 1.05
Specificity of glycopeptide-specific T cells. J Immunol (1995) 1.04
Quality of life after heart valve replacement. J Heart Valve Dis (1992) 1.04
Verification of proton range, position, and intensity in IMPT with a 3D liquid scintillator detector system. Med Phys (2012) 1.03
On the use of EPID-based implanted marker tracking for 4D radiotherapy. Med Phys (2004) 1.02
Vertebral artery dissection with a normal-appearing lumen at multisection CT angiography: the importance of identifying wall hematoma. AJNR Am J Neuroradiol (2009) 1.02
Differential pencil beam dose computation model for photons. Med Phys (1986) 1.02
Assessing optimal fermentation type for bio-hydrogen production in continuous-flow acidogenic reactors. Bioresour Technol (2006) 1.02
A comparison of three stereotactic radiotherapy techniques; ARCS vs. noncoplanar fixed fields vs. intensity modulation. Int J Radiat Oncol Biol Phys (1998) 1.01
A method of incorporating organ motion uncertainties into three-dimensional conformal treatment plans. Int J Radiat Oncol Biol Phys (1996) 1.01
MEK2 is a kinase related to MEK1 and is differentially expressed in murine tissues. Cell Growth Differ (1993) 1.01
Increased LDL cholesterol in non-insulin-dependent diabetics with maculopathy. Acta Diabetol Lat (1984) 1.01
Natural and experimental infection of turkeys with avian paramyxovirus-7. Avian Dis (1997) 1.00
Intensity-modulated stereotactic radiosurgery using dynamic micro-multileaf collimation. Int J Radiat Oncol Biol Phys (2001) 1.00
The evidence base of complementary and alternative therapies in depression. J Affect Disord (2006) 0.99
A flattening filter free photon treatment concept evaluation with Monte Carlo. Med Phys (2006) 0.98
Cells adapted to the proteasome inhibitor 4-hydroxy- 5-iodo-3-nitrophenylacetyl-Leu-Leu-leucinal-vinyl sulfone require enzymatically active proteasomes for continued survival. Proc Natl Acad Sci U S A (2001) 0.98
A Monte Carlo study of radiation transport through multileaf collimators. Med Phys (2001) 0.97
Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett (1999) 0.96
Validity and reliability of reported dietary intake data. J Am Diet Assoc (1994) 0.96
Steroid induced glaucoma and cataract. Indian J Ophthalmol (1989) 0.96
Tropical pancreatic diabetes in South India: heterogeneity in clinical and biochemical profile. Diabetologia (1985) 0.94
A method for determining multileaf collimator transmission and scatter for dynamic intensity modulated radiotherapy. Med Phys (2000) 0.94
A Monte Carlo model of photon beams used in radiation therapy. Med Phys (1995) 0.94
Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med (1993) 0.94
Wound epidermis formation and function in urodele amphibian limb regeneration. Cell Mol Life Sci (2008) 0.94
Oxidative stress and the development of diabetic complications--antioxidants and lipid peroxidation in erythrocytes and cell membrane. Cell Biol Int (1995) 0.93
Validation of Monte Carlo generated phase-space descriptions of medical linear accelerators. Med Phys (1999) 0.93
Sources of electron contamination for the Clinac-35 25-MV photon beam. Med Phys (1984) 0.92
Cancer chemotherapy and heterocyclic compounds. Curr Med Chem (2002) 0.92
Plant peroxidase gene expression and function. Biochem Soc Trans (1992) 0.92
Small-molecule inhibitors of the cell cycle. Curr Opin Chem Biol (2000) 0.92